{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:03:40Z","timestamp":1789473820202,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"DOI":"10.7759\/cureus.102866","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:57:17Z","timestamp":1770105437000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits"],"prefix":"10.7759","author":[{"given":"Kumar Prafull","family":"Chandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukulesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunkumar R","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanusree","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shally","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Lachhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","unstructured":"2. Diagnosis and classification of diabetes. standards of care in diabetes-2024. Diabetes Care. 2024, 47:S20-42. 10.2337\/dc24-S002","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun H","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022, 183:109119. 10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.25259\/NMJI_655_23","article-title":"Lessons learnt from the ICMR-Indiab study","volume":"36","author":"Mohan V","year":"2023","unstructured":"Mohan V, Anjana RM, Tandon N. Lessons learnt from the ICMR-Indiab study. Natl Med J India. 2023, 36:137-9. 10.25259\/NMJI_655_23","journal-title":"Natl Med J India"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo RA","year":"2015","unstructured":"DeFronzo RA, Ferrannini E, Groop L, et al.. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015, 1:15019. 10.1038\/nrdp.2015.19","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck MA","year":"2016","unstructured":"Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016, 4:525-36. 10.1016\/S2213-8587(15)00482-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun T","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018, 18:3-14. 10.1016\/j.molmet.2018.09.009","journal-title":"Mol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms RJ","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1?. Trends Endocrinol Metab. 2020, 31:410-21. 10.1016\/j.tem.2020.02.006","journal-title":"Trends Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik B","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398:583-98. 10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021, 398:1811-24. 10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"key":"ref15","unstructured":"U.S. Food and Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes. (2022). Accessed: December 6. (2024). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-dual-targeted-treatment-type-2-diabetes."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06838.x","article-title":"Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations","volume":"1281","author":"Gujral UP","year":"2013","unstructured":"Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013, 1281:51-63. 10.1111\/j.1749-6632.2012.06838.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1595","article-title":"Obesity and the metabolic syndrome in developing countries","volume":"93","author":"Misra A","year":"2008","unstructured":"Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008, 93:S9-30. 10.1210\/jc.2008-1595","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.163171","article-title":"Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement","volume":"19","author":"Kalra S","year":"2015","unstructured":"Kalra S, Aamir AH, Raza A, et al.. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015, 19:577-96. 10.4103\/2230-8210.163171","journal-title":"Indian J Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/ijdt.ijdt_15_25","article-title":"Unraveling the dual burden of diabetes and obesity: precision strategies for South Asian populations","volume":"Jul-Sep","author":"Samajdar SS","year":"2025","unstructured":"Samajdar SS, Saboo B, Joshi S. Unraveling the dual burden of diabetes and obesity: precision strategies for South Asian populations. International Journal of Diabetes and Technology. 2025, Jul-Sep:55-66. 10.4103\/ijdt.ijdt_15_25","journal-title":"International Journal of Diabetes and Technology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - What is it and what can it tell us?","volume":"375","author":"Sherman RE","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al.. Real-world evidence - What is it and what can it tell us?. N Engl J Med. 2016, 375:2293-7. 10.1056\/NEJMsb1609216","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde L","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018, 35:1763-74. 10.1007\/s12325-018-0805-y","journal-title":"Adv Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007, 335:806-8. 10.1136\/bmj.39335.541782.AD","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH)","volume":"37","author":"Baber N","year":"1994","unstructured":"Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol. 1994, 37:401-4. 10.1111\/j.1365-2125.1994.tb05705.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes-2024","volume":"47","year":"2024","unstructured":"6. Glycemic goals and hypoglycemia. standards of care in diabetes-2024. Diabetes Care. 2024, 47:S111-25. 10.2337\/dc24-S006","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling RK","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006, 43:1317-25. 10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.s1-5.1.26","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald WT","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18:499-502. 10.1136\/jcp.s1-5.1.26","journal-title":"Clin Chem"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey AS","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009, 150:604-12. 10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013, 310:2191-4. 10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2015.02.006","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the study of the liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology","volume":"5","author":"Duseja A","year":"2015","unstructured":"Duseja A, Singh SP, Saraswat VA, et al.. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the study of the liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015, 5:51-68. 10.1016\/j.jceh.2015.02.006","journal-title":"J Clin Exp Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13243","article-title":"Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?","volume":"20","author":"Khunti K","year":"2018","unstructured":"Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. Diabetes Obes Metab. 2018, 20:1337-41. 10.1111\/dom.13243","journal-title":"Diabetes Obes Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_24_18","article-title":"Out-of-pocket expenditure and drug adherence of patients with diabetes in Odisha","volume":"7","author":"Swain SP","year":"2018","unstructured":"Swain SP, Samal S, Sahu KS, Rout SK. Out-of-pocket expenditure and drug adherence of patients with diabetes in Odisha. J Family Med Prim Care. 2018, 7:1229-35. 10.4103\/jfmpc.jfmpc_24_18","journal-title":"J Family Med Prim Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70058","article-title":"Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice","volume":"33","author":"Gasoyan H","year":"2025","unstructured":"Gasoyan H, Butsch WS, Casacchia NJ, et al.. Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity (Silver Spring). 2025, 33:2296-303. 10.1002\/oby.70058","journal-title":"Obesity (Silver Spring)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458192-real-world-evidence-of-tirzepatide-in-indian-adults-with-type-2-diabetes-significant-early-glycemic-and-cardiometabolic-benefits","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:57:18Z","timestamp":1770105438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458192-real-world-evidence-of-tirzepatide-in-indian-adults-with-type-2-diabetes-significant-early-glycemic-and-cardiometabolic-benefits"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.102866","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}